ALIVE Israel Healthtech Fund

Navina is a technology company that specializes in developing an AI-driven platform aimed at transforming patient data into clear and actionable patient portraits. This innovative platform addresses the challenges posed by disorganized patient information, allowing physicians to quickly assess complex cases and make informed diagnoses. By utilizing artificial intelligence and machine learning, Navina's technology organizes critical data to highlight essential clinical insights, enabling healthcare providers to enhance patient care while increasing efficiency at the point of care. The platform not only aims to improve patient outcomes but also contributes to better financial performance for healthcare providers and payers. Additionally, Navina collaborates with the American Academy of Family Physicians Innovation Lab to further its mission in the healthcare sector.

Magenta Medical Ltd. is a privately held company founded in 2012 and headquartered in Kadima, Israel. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its primary product line includes a temporary venous catheter-based therapy and a self-expanding heart pump designed to address key issues associated with acute heart failure, such as renal venous congestion. By enabling cardiac specialists to more effectively manage fluid and salt removal, Magenta Medical's solutions aim to improve patient outcomes while safeguarding kidney function.

Vessi Medical is an Israeli medical device startup focused on innovating treatment for Non-Muscle-Invasive Bladder Cancer (NMIBC) through a novel surface cryotherapy approach. This technique employs extreme cold to freeze and eliminate abnormal tissue, providing a minimally invasive alternative to the standard TransUrethral Resection of Bladder Tumor (TURBT), which is often inadequate and requires invasive surgery under general anesthesia. Vessi's technology, comprising a standalone console and a disposable catheter, allows for targeted cell destruction while safeguarding healthy bladder tissue. This office-based procedure not only reduces the need for costly hospital stays and repeat surgeries but also addresses the high recurrence rate of NMIBC, which affects millions globally. With promising proof of concept already demonstrated in animal studies, Vessi aims to capture the $1.2 billion NMIBC market, while also exploring future applications for treating overactive bladder and urinary tract infections. The company is supported by experienced professionals in the medical device and cryotherapy sectors, ensuring a strong foundation for its innovations.

Gina Life is femtech company developing a platform of biomarkers strategy supported by AI for early detection in women’s health space.

Append Medical is a medical technology company focused on developing an innovative transcatheter Left Atrial Appendage (LAA) closure system aimed at preventing strokes by reducing the risk of blood clots traveling to the brain. The company’s approach involves a uniquely designed system that eliminates the LAA through tissue invagination and suture closure, providing a simplified alternative to traditional implant-based LAA closures. This method is intended to minimize the presence of foreign materials at the closure site, thereby reducing device-related thromboembolism risks. Currently in the pre-clinical in-vivo trial phase, Append Medical operates within a market projected to grow significantly, with estimates suggesting the LAA closure market could reach $25 billion in the coming years. The company is also affiliated with MEDX Xelerator, a medtech incubator supported by several prominent organizations.

Magenta Medical Ltd. is a privately held company founded in 2012 and headquartered in Kadima, Israel. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its primary product line includes a temporary venous catheter-based therapy and a self-expanding heart pump designed to address key issues associated with acute heart failure, such as renal venous congestion. By enabling cardiac specialists to more effectively manage fluid and salt removal, Magenta Medical's solutions aim to improve patient outcomes while safeguarding kidney function.

Thesis offers personalized brain supplements that cater to all types of brains. They create potent nutritional compounds to improve mental function and provide individualized suggestions depending on their customers' goals and brain chemistry.

Wisdo Health is an AI-powered social health platform focused on enhancing mental and physical well-being by fostering meaningful connections among users. The company offers an evidence-based peer support and benefits navigation platform that addresses the detrimental effects of social isolation and loneliness. By connecting individuals with shared experiences, Wisdo Health aims to improve health outcomes and reduce medical costs. The platform empowers users to learn from one another, facilitating personal growth and resilience in the face of life’s challenges and opportunities.

Navina is a technology company that specializes in developing an AI-driven platform aimed at transforming patient data into clear and actionable patient portraits. This innovative platform addresses the challenges posed by disorganized patient information, allowing physicians to quickly assess complex cases and make informed diagnoses. By utilizing artificial intelligence and machine learning, Navina's technology organizes critical data to highlight essential clinical insights, enabling healthcare providers to enhance patient care while increasing efficiency at the point of care. The platform not only aims to improve patient outcomes but also contributes to better financial performance for healthcare providers and payers. Additionally, Navina collaborates with the American Academy of Family Physicians Innovation Lab to further its mission in the healthcare sector.

OncoHost is a clinical-stage biotechnology company based in Binyamina, Israel, focused on developing personalized strategies to enhance the efficacy of cancer therapies. Founded in 2017, the company leverages proprietary proteomic analysis to gain insights into individual patient responses to treatment, addressing the significant challenge of therapy resistance in oncology. By analyzing proteomic changes in blood samples, OncoHost's platform facilitates the early identification of patients likely to be non-responsive to cancer treatments and aids in discovering new drug targets. This innovative approach combines bioinformatics, systems biology, and machine learning to provide healthcare institutions with critical information regarding predicted clinical benefits from therapies, ultimately enabling the development of tailored treatment strategies that aim to improve patient outcomes and minimize side effects. Through extensive clinical programs in collaboration with leading academic and clinical partners, OncoHost positions itself at the forefront of precision cancer medicine.

Beyeonics is a medical technology company founded in 2012, based in Israel, and comprised of former senior engineers from Elbit Systems. The company is focused on transforming surgical visualization and information delivery through innovative virtual and augmented reality solutions. Beyeonics' technology aims to replace traditional surgical microscopes, allowing for real-time integration of extensive data during procedures. This advancement enhances surgeons' efficiency, patient safety, and overall surgical outcomes. The company is developing visualization systems for various surgical applications, including spine surgery, minimally invasive procedures, robotic surgery, and use in cardiovascular catheterization labs. Beyeonics collaborates with leading medical professionals and institutions, including experts from the Tel Aviv Sourasky Medical Center and Retinal Consultants of Arizona, to further its mission of improving surgical practices.

Innovalve is an early-stage medical device company founded in 2017 and based in Israel. The company specializes in developing catheter-based heart valve therapies aimed at treating cardiovascular diseases. Its innovative technology features an artificial mitral valve that can be implanted through a minimally invasive catheter, providing an alternative approach for healthcare professionals in managing patients with heart conditions. By focusing on less invasive techniques, Innovalve aims to improve patient outcomes and broaden treatment options in the field of cardiac surgery.